

## Special Issue

# Cancer Immunotherapy: Molecular Mechanisms and Novel Potential Targets

### Message from the Guest Editors

In recent decades scientists have made significant progress in deciphering the molecular mechanisms involved in cancer immune surveillance and immune escape, helping to develop novel and more effective immunotherapies, including oncolytic virus therapies, cytokines therapies, cancer vaccines, immune checkpoint inhibitors and adoptive cell transfer. This Special Issue encourages authors to present recent progress in the following areas:

- Discerning undefined interactions between immune cells and tumor cells or stroma (cell–cell inhibition, ECM, CAFs, distal stroma and metastases)
- Discovering novel putative targets (i.e., neo-antigens, cytokines and receptors) to develop more specific and successful therapies,
- Eliciting the different genetic (i.e., HLA, non-coding RNA) and environmental (i.e., microbiome, virus infections, co-morbidity) contexts that may affect the outcome of cancer immunotherapies.

In this Special Issue, original research articles and reviews are welcome. Dr. Biancamaria Ricci

---

### Guest Editors

Dr. Francesca Romana Mariotti

Dr. Martina Molgora

Dr. Linda Quatrini

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/158386](https://mdpi.com/si/158386)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).